The phase 1/2 clinical trial (NCT04120493) of AMT-130 (uniQure) for the treatment of patients with Huntington disease has met its prespecified primary end point, with a high dose of the gene therapy candidate demonstrating statistically significant s... [4565 chars].. reed more
